Dinah Tzemach
Hebrew University of Jerusalem
10 Papers
103 Citations
Dinah Tzemach is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Liposome & Drug carrier. The author has an hindex of 9, co-authored 10 publications.
Chat about Author
Papers
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Olga Lyass,Beatrice Uziely,Rami Ben-Yosef,Dinah Tzemach,Norman I. Heshing,Michal Lotem,George Brufman,Alberto Gabizon +7 more
TL;DR: Doxil (ALZA Corp., Mountain View, CA) is a formulation of doxorubicin in polyethylene‐glycol coated liposomes with a prolonged circulation time and unique toxicity profile.
400
Selective Delivery of Doxorubicin to Patients with Breast Carcinoma Metastases by Stealth Liposomes
TL;DR: Whether stealth liposomal doxorubicin accumulates selectively in bone metastases based on clinical material obtained from two patients with breast carcinoma is determined.
210
Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines.
TL;DR: Longevity in circulation, as obtained with PEG coating, tends to improve the therapeutic efficacy of liposome-encapsulated anthracyclines.
103
Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes
TL;DR: Delivery of MLP in pegylated liposomes is a potential approach for effective treatment of multidrug-resistant tumors while significantly buffering the toxicity of MMC.
101
•Journal Article
Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
TL;DR: Overall, Doxil given by the systemic i.v. route was the most effective treatment in prolonging median survival and obtaining cures and variations in the dose-schedule treatment regime confirm the superior therapeutic profile and reduced dependence on tumor burden of the PEGylated liposomal formulation over free drug.
70